Midi Health Review
Best for: women in menopause / perimenopause with commercial insurance who want GLP-1 prescribing as part of a broader hormone + metabolic care plan, not as a standalone weight-loss product
Midi Health is a nationwide 50-state menopause and perimenopause telehealth platform. GLP-1 prescribing is offered as a clinician-discretionary metabolic-health adjunct within the menopause care framework — not as a standalone weight-loss product. Accepts commercial insurance but does NOT accept Medicare, Medicaid, or Medi-Cal.
Medium confidence · Last verified 2026-04-09 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Midi Health is a solid telehealth option with balanced features and pricing.
Score Breakdown
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compounded semaglutide (uninsured starting) | compounded | $128 |
✓ Pros
- •Nationwide availability in all 50 states (verified on the public homepage)
- •Accepts commercial insurance — differentiator vs most cash-pay-only GLP-1 telehealth
- •Menopause + metabolic health specialty framing — useful for women in the demographic where GLP-1 efficacy and weight regulation overlap most
- •Compounded semaglutide pricing starts at $127.90/mo for uninsured patients per the public pricing/insurance page
✗ Cons
- •Does NOT accept Medicare, Medicaid, or Medi-Cal — eliminates roughly 40% of the insured US adult population
- •GLP-1 prescribing is clinician-discretionary inside a broader menopause care plan, NOT a guaranteed offering at intake — readers signing up purely for GLP-1 access may not get it
- •Menopause-focused — not the right fit for men or younger women whose primary need is weight loss
Ready to start with Midi Health?
Starting at $128/month. See current pricing and start your free consultation.
Sources & methodology
Our Midi Health review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
Alternatives to Midi Health
Editorial score · methodology
Editorial score · methodology
Alloy
Best for: women in menopause/perimenopause who want a Menopause Society-certified clinician AND the broadest brand+compounded GLP-1 formulary in our directory
Editorial score · methodology
Frequently Asked Questions
Ready to start with Midi Health?
Starting at $128/month. See current pricing and start your free consultation.